A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-10-20
Adverse events
Grade 4 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-21 (study day 47); relationship: not assessed; serious criteria: life-threatening
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-02-16 (study day 104); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-08-19 (study day 288); relationship: N
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-02-05 (study day 458); relationship: not assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-02-13 (study day 466); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-06-01 (study day 575); relationship: N
Data queries
No data queries.